Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qidan Xiaoke Granules in Patients After Coronary Revascularization
NCT07616544Phase 3Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jun 2028
01
Overview
Phase 3, randomised, double-blind trial in coronary artery disease (CAD) (2 arms). Primary endpoint: Incidence Rate of Major Adverse Cardiovascular Events at 48 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07616544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616544.